Application of micromolecular polypeptide KP-6 in preparing drug for treating chronic kidney disease

A technology for small molecule peptides and chronic kidney disease, applied in the field of biomedicine

Active Publication Date: 2017-06-13
NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV
View PDF2 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are still no effective drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of micromolecular polypeptide KP-6 in preparing drug for treating chronic kidney disease
  • Application of micromolecular polypeptide KP-6 in preparing drug for treating chronic kidney disease
  • Application of micromolecular polypeptide KP-6 in preparing drug for treating chronic kidney disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Example 1: Screening of KP-6 Small Molecular Peptides

[0024] 1. Experimental materials:

[0025] Cells: Human renal tubular epithelial cells.

[0026] Culture medium: DMEM / F129 (1:1) culture medium containing 10% FBS.

[0027] Culture conditions: 37°C with 5% CO 2 incubator.

[0028] Small molecule peptide library: 18 peptide sequences were designed by computer, each with an average length of 30 amino acids, which were artificially synthesized by Nanjing GenScript Biotechnology Co., Ltd. to build a small molecule peptide library and conduct the following experiments.

[0029] 2. Experimental treatment:

[0030] (I) Cultured human renal tubular epithelial cells were mixed with 1.5×10 6 Planted in 6-well cell culture plate, cultured for 1 day, starved for 24 hours, and given 18 different small molecular polypeptides (10 μg / ml) 1 hour in advance. Then the Wnt1 plasmid was transfected, and the protein was harvested 24 hours later, and Western blot experiments were p...

Embodiment 2

[0037] Example 2: Inhibitory effect of small molecule polypeptide KP-6 on renal fibrosis in mouse UUO model

[0038] 1. Experimental animals: C57 mice, male and female matched, weighing 20-22g, SPF grade.

[0039]The animals were first weighed and numbered, and 12 healthy mice weighing 20-22 g were selected and randomly divided into 3 groups with 4 mice in each group. Including sham operation group, model control group and medication group.

[0040] 2. Experimental grouping

[0041] 1) Sham operation group: room temperature, 3% pentobarbital sodium anesthetized mice with 1ml / kg body weight, select the left abdomen 2-3cm as the incision; after local disinfection, cut the skin, subcutaneous, muscle layer and After the peritoneum was discovered, the left ureter was sutured layer by layer. After local disinfection, check the marks and place them in corresponding mouse cages.

[0042] 2) Model control group: anesthetized and disinfected as above. The skin, subcutaneous layer, ...

Embodiment 3

[0054] Example 3: Inhibitory effect of small molecule polypeptide KP-6 on renal fibrosis in mouse UIRI model

[0055] 1. Experimental animals: BABL / c mice, male, weighing 20-22g, SPF grade.

[0056] The animals were first weighed and numbered, and 18 healthy mice weighing 20-22 g were selected and randomly divided into 3 groups, 6 in each group. Including normal saline group, model control group and medication group.

[0057] 2. Experimental groups

[0058] 1) Sham operation group: room temperature, 3% pentobarbital sodium anesthetized mice with 1ml / kg body weight, select the left abdomen 2-3cm as the incision; after local disinfection, cut the skin, subcutaneous, muscle layer and The peritoneum was sutured layer by layer after the left renal pedicle was found. After local disinfection, check the marks and place them in corresponding mouse cages.

[0059] 2) Model control group: anesthetized and disinfected as above. Cut the skin, subcutaneous layer, muscle layer and peri...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of biological medicine, and relates to application of micromolecular polypeptide KP-6, in particular to application of micromolecular polypeptide KP-6 in preparing a drug for treating a chronic kidney disease (CKD). An amino acid sequence of the polypeptide KP-6 is shown as SEQ ID NO. 1. The micromolecular polypeptide KP-6 has a significant effect of inhibiting kidney tissue fibrosis and CKD development, has no obvious toxic or side effects, and therefore can be used for preparing the drug for effectively treating the chronic kidney disease.

Description

technical field [0001] The invention belongs to the field of biomedicine and relates to the use of a unique small molecule polypeptide in the treatment of chronic kidney disease (CKD), in particular to the use of KP-6 polypeptide in the preparation of CKD medicines. Background technique [0002] Chronic kidney disease (CKD) eventually progresses to end-stage renal failure (ESRD), and patients rely on "renal replacement therapy" for life to maintain their lives. In the past few decades, along with the aging of the human society, the prevalence of CKD has been increasing year by year (Nat Rev Nephrol, 2011, 7:684-696). Some data indicate that CKD is becoming a "public health problem", which seriously endangers human health and consumes a lot of health resources. However, currently there are no drugs that can effectively delay the progression of CKD clinically. Aiming at the pathogenesis of CKD, finding drugs that can effectively inhibit or delay the progress of CKD is undoub...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/16A61P13/12
CPCA61K38/16
Inventor 刘友华周丽丽
Owner NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap